NEXTGEN BIOMED LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.1 ILa | +3.60% |
|
+0.36% | -11.87% |
| 2023 | Nextgen Biomed Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Nextgen Biomed Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 27.18M 10.25B |
|---|---|---|---|---|---|
| Net income 2021 | -2M -754M | Net income 2022 | -8M -3.02B | EV / Sales 2021 | - |
| Net cash position 2021 | 11.96M 4.51B | Net cash position 2022 | 5.24M 1.98B | EV / Sales 2022 | - |
| P/E ratio 2021 |
-21.7
x | P/E ratio 2022 |
-3.17
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 92.33% |
More Fundamentals
* Assessed data
| 1 day | +3.60% | ||
| 1 week | +0.36% | ||
| Current month | +4.86% | ||
| 1 month | +6.26% | ||
| 3 months | -11.87% | ||
| 6 months | -45.56% | ||
| Current year | -11.87% |
1 week
100.00
118.80
1 month
98.00150.00
Current year
95.00150.00
1 year
95.00372.00
3 years
95.003 390.00
5 years
95.004 381.20
10 years
79.206 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 22-11-19 | |
Dalia Mulakandov
DFI | Director of Finance/CFO | 39 | 23-01-16 |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 00-08-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Grossman
BRD | Director/Board Member | 49 | 22-06-11 |
Yaacov Amidror
CHM | Chairman | 75 | 21-01-06 |
Alon Pinkas
BRD | Director/Board Member | 62 | 22-11-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-21 | 112.1 | +3.60% | 3,485 |
| 24-04-18 | 108.2 | +3.34% | 17,857 |
| 24-04-17 | 104.7 | -1.97% | 16,127 |
| 24-04-16 | 106.8 | -4.39% | 15,833 |
| 24-04-15 | 111.7 | -2.02% | 11,655 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 21, 2024 at 08:49 am EDT
More quotes
Nextgen Biomed Ltd is an Israel-based research and development company. Its main activity is to own EyePen product. The Company's product is dedicated to people with diabetes and consists of an injection module which allows to monitor the doses and time of insulin intake. The EyePen mobile app keeps diabetes management systematic by monitoring behavior and provides alerts for human errors such as forgetting a pen, double insulin injections, or skipping injections.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.87% | 2.14M | |
| +18.73% | 28.89B | |
| -34.30% | 2.83B | |
| -8.99% | 2.7B | |
| -2.44% | 2.01B | |
| -0.74% | 1.88B | |
| -11.44% | 1.79B | |
| -6.11% | 1.37B | |
| +14.59% | 1.13B | |
| +3.86% | 1.06B |
- Stock Market
- Equities
- NXGN Stock
